Q2 2026 saw strong revenue and adjusted EBITDA growth, with significant contributions from new partnerships and transformation initiatives. Despite temporary headwinds from Medicare and commission changes, guidance anticipates accelerating organic growth and margin expansion in the second half of 2026.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.